+++
# â”€â”€â”€ğŸ—‚ï¸ åŸºç¡€ä¿¡æ¯â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
type          = "posts"
date          = 2026-02-14T13:52:58+08:00
lastmod       = 2026-02-14T13:52:58+08:00
slug          = ""
title         = "åŒ»è¯ç›‘ç®¡å‘¨åˆŠ - 2026-02-14"

# â”€â”€â”€âš™ï¸ æ¸²æŸ“æ§åˆ¶â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
toc           = true
math          = false
mermaid       = false
gallery       = false
weight        = 0

# â”€â”€â”€ğŸ› ï¸ å¢å¼ºè®¾ç½®â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
draft          = false
aliases        = []
expiryDate     = ""
paid           = false
license        = ""
featuredImage  = ""

# â”€â”€â”€ğŸ“ˆ æ–‡ç« å±æ€§â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
description   = "åŒ»è¯ç›‘ç®¡å‘¨åˆŠå‘¨åˆŠï¼Œæ¶µç›–ç›‘ç®¡åŠ¨æ€ä¸æ–°è¯å®¡æ‰¹ã€‚"
keywords       = ["åŒ»è¯", "ç›‘ç®¡", "æ–°é—»"]
author         = [""]
series         = [""]
categories     = ["pharma"]
tags           = ["EMA", "FDA"]
+++

## æ–°è¯é€Ÿé€’

FDA 2026-02-12 [Keytruda and Keytruda Qlex, Plus Paclitaxel Â± Bevacizumab, Approved for Certain Adults with PD-L1+ (CPS â‰¥1) Platinum-Resistant Ovarian Carcinoma](https://www.drugs.com/newdrugs/keytruda-keytruda-qlex-plus-paclitaxel-bevacizumab-approved-certain-adults-pd-l1-cps-1-platinum-6723.html)

FDA 2026-02-11 [NIH Halts Arm of Clinical Trial Evaluating a Potential Stroke Treatment](https://www.drugs.com/clinical_trials/nih-halts-arm-clinical-trial-evaluating-potential-stroke-22303.html)

FDA 2026-02-10 [Moderna Receives Refusal-to-File Letter from the U.S. Food and Drug Administration for Its Investigational Seasonal Influenza Vaccine, mRNA-1010](https://www.drugs.com/clinical_trials/moderna-receives-refusal-file-letter-u-s-food-administration-investigational-seasonal-influenza-22304.html)

FDA 2026-02-08 [Genentechâ€™s Fenebrutinib Is the First Investigational Medicine in Over a Decade That Reduces Disability Progression in Primary Progressive Multiple Sclerosis (PPMS)](https://www.drugs.com/clinical_trials/genentech-s-fenebrutinib-first-investigational-medicine-over-decade-reduces-disability-progression-22299.html)

## ç›‘ç®¡åŠ¨æ€

FDA 2026-02-14 [Zydus Lifesciences Limited - 9/5/2025](http://www.fda.gov/drugs/cder-foia-electronic-reading-room/zydus-lifesciences-limited-952025)

FDA 2026-02-13 [Eugia Pharma Specialities Limited - 2/6/2026](http://www.fda.gov/drugs/cder-foia-electronic-reading-room/eugia-pharma-specialities-limited-262026)

FDA 2026-02-11 [F.H. Investments Inc dba Asteria Health. Birmingham, AL. 483 issued 12/19/2025](http://www.fda.gov/about-fda/fda-commissioner/fh-investments-inc-dba-asteria-health-birmingham-al-483-issued-12192025)

EMA 2026-02-13 [Concept paper for the revision of the guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal Management (EMA/522332/2021)](https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guideline-veterinary-good-pharmacovigilance-practices-vgvp-module-signal-management-ema-522332-2021_en.pdf)

EMA 2026-02-13 [Concept paper on the need of a guideline on clinical investigation of medicinal products in the treatment of Myasthenia Gravis](https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-guideline-clinical-investigation-medicinal-products-treatment-myasthenia-gravis_en.pdf)

EMA 2026-02-09 [Concept paper on the revision of the guidelines on Good Manufacturing Practice for medicinal products - Annex 15 - Qualification and validation](https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guidelines-good-manufacturing-practice-medicinal-products-annex-15-qualification-validation_en.pdf)

## æ³•è§„æŒ‡å—

EMA 2026-02-12 [Guidance for applicants for the preparation of the precise scope section of the variation application form](https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-applicants-preparation-precise-scope-section-variation-application-form_en.pdf)

EMA 2026-02-10 [Validation checklist for Type II quality variations](https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/validation-checklist-type-ii-quality-variations_en.docx)

